The U.S. Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) market is poised for significant growth over the coming decade, with projected market size expected to reach US$149.4 billion by 2032, up from US$83.1 billion in 2025, registering a robust CAGR of 8.7% during the forecast period of 2025-2032. This growth trajectory is underpinned by the rising demand for comprehensive services spanning active pharmaceutical ingredient (API) manufacturing, formulation development, packaging, and labeling, catering to both pharmaceutical and biopharmaceutical sectors.
Historical Market Overview (2019-2024)
Over the past five years, the U.S. CMO/CDMO market has witnessed steady expansion driven by the increasing outsourcing trends among pharmaceutical companies. Between 2019 and 2024, the market benefitted from heightened demand for specialized manufacturing capabilities, accelerated by the COVID-19 pandemic, which highlighted the critical need for scalable and flexible production solutions. Companies increasingly leveraged CMOs and CDMOs for drug discovery, clinical trial support, and commercial-scale production, reducing operational complexities and capital expenditure while ensuring regulatory compliance.
Forecast Period Analysis (2025-2032)
The forecast period is marked by sustained growth, with market valuations projected to rise from US$83.1 billion in 2025 to US$149.4 billion by 2032. The expansion is attributed to several key drivers including the rising prevalence of chronic diseases, oncology and rare disease therapeutics, and advanced biologics manufacturing. Increasing investments in biopharmaceutical research, gene therapy, and personalized medicine are also expected to further accelerate outsourcing activities, particularly in API manufacturing and finished dosage formulation.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35634
Market Segmentation Analysis
By Service:
The market is segmented into drug discovery and development, API manufacturing, finished dosage formulation development, and packaging/distribution. API manufacturing remains a cornerstone of the market, driven by the need for high-quality, scalable, and cost-effective production. Finished dosage formulation development and drug discovery services are also witnessing heightened demand as pharmaceutical companies increasingly rely on external partners for preclinical and clinical trial support. Packaging and distribution services are becoming strategically important due to the growing complexity of drug delivery systems and the need for compliance with regulatory and safety standards.
By Scale of Operation:
The CMO/CDMO market operates across preclinical, clinical, and commercial-scale operations. Preclinical and clinical operations dominate early-stage outsourcing, whereas commercial-scale manufacturing continues to expand due to rising demand for large-volume production, biologics, and high-value therapeutics. Companies providing end-to-end solutions across multiple stages of drug development are increasingly preferred, allowing sponsors to optimize timelines and mitigate risks.
By Organization Size:
Market players are categorized into small, mid-sized, and large-sized organizations. Large-scale organizations continue to dominate due to their established infrastructure, technological capabilities, and regulatory expertise, enabling them to handle complex biopharmaceutical projects. Mid-sized and small-sized companies, however, are gaining traction by focusing on niche services, specialized therapeutic areas, and flexible manufacturing models.
By Therapeutic Area:
The therapeutic segmentation covers infectious diseases, oncology, CNS, cardiovascular, respiratory, and other areas. Oncology remains the largest segment owing to the increasing prevalence of cancer and high demand for targeted therapies and biologics. Infectious disease therapeutics gained renewed focus during the pandemic, while CNS and cardiovascular disorders are driving demand for innovative formulation development and sustained-release drug delivery solutions.
Geographical Coverage
The report focuses exclusively on the United States, a market characterized by advanced regulatory frameworks, a robust healthcare infrastructure, and high R&D investments. The U.S. remains a hub for biopharmaceutical innovation, further propelling the demand for contract manufacturing and development services.
Competitive Landscape
The U.S. CMO/CDMO sector is highly competitive, comprising both global giants and specialized regional players. Key market participants include Thermo Fisher Scientific Inc., AGC Biologics, Curia Global, Inc., LGM Pharma, Cell Culture Company, LLC, Ascendia Pharmaceutical Solutions, Kindeva, Crystal Pharmatech Co., Ltd., Asymchem Inc., Pharmaceutics International, Inc., Catalent, Inc., Cambrex Corporation, CARBOGEN AMCIS, Lonza, Bora Pharmaceuticals, BioSpring, Quotient Sciences, Hillgene Biopharma Co., Ltd., CMIC HOLDINGS Co., LTD., Evonik, Novartis AG, Piramal Pharma Limited, CordenPharma, and Recipharm AB.
These companies are engaged in strategic growth initiatives including capacity expansion, mergers and acquisitions, partnerships, and technology upgrades to enhance service portfolios and capture a larger market share. The competitive intensity is further heightened by the increasing need for integrated solutions spanning drug discovery to commercial manufacturing.
Market Drivers
Several factors are driving the robust growth of the U.S. CMO/CDMO market:
Rising Outsourcing Trends: Pharmaceutical companies continue to outsource manufacturing and development activities to reduce operational costs and focus on core competencies.
Growth of Biopharmaceuticals: Increasing investment in biologics, vaccines, and gene therapies is driving demand for specialized manufacturing services.
Regulatory Compliance and Risk Mitigation: Outsourcing enables companies to leverage the expertise of CMOs/CDMOs in navigating complex regulatory landscapes.
Technological Advancements: Adoption of continuous manufacturing, advanced analytics, and automated processes enhances efficiency and scalability.
Strategic Partnerships and Collaborations: Companies are forming alliances to expand geographic reach, diversify service offerings, and accelerate product development.
Challenges and Market Constraints
Despite the positive growth outlook, the market faces several challenges:
High Initial Investment: Establishing state-of-the-art manufacturing facilities requires substantial capital investment.
Regulatory Complexity: Compliance with FDA and other regulatory requirements remains a significant challenge.
Supply Chain Vulnerabilities: Dependence on raw material suppliers and geopolitical uncertainties can impact production timelines.
Competition: Intense competition among large global players and agile regional firms may affect profitability and market positioning.
Strategic Growth Initiatives
Market players are increasingly adopting strategic initiatives to strengthen market position and expand service capabilities:
Capacity Expansion: Scaling up manufacturing capabilities to meet rising demand for large-volume biologics and novel therapies.
Mergers and Acquisitions: Integrating smaller specialized firms to diversify service offerings and enhance technological expertise.
Technology Adoption: Implementing continuous manufacturing, single-use systems, and AI-driven process optimization for operational efficiency.
Market Penetration: Expanding into emerging therapeutic areas and investing in niche markets such as orphan drugs and personalized medicine.
Pricing Analysis
The pricing structure in the U.S. CMO/CDMO market is influenced by service type, scale of operation, therapeutic complexity, and regulatory requirements. API manufacturing and specialized biologics services command premium pricing due to high technical complexity and stringent quality standards. Companies are increasingly adopting flexible pricing models to remain competitive and attract long-term partnerships.
Future Opportunities and Revenue Pockets
Several growth opportunities are emerging in the U.S. CMO/CDMO market:
Gene Therapy and Cell Therapy Manufacturing: Rising demand for advanced therapies is creating new revenue streams.
Integrated End-to-End Solutions: Offering services from drug discovery to commercial distribution ensures client retention and higher revenue.
Contract Research Services: Expansion into early-stage research and development provides additional market growth.
Sustainability Initiatives: Green manufacturing and environmentally sustainable practices are becoming differentiators for market players.
Conclusion
The U.S. CMO/CDMO market is on a strong growth trajectory, with valuations expected to nearly double by 2032. Fueled by the increasing demand for outsourcing, expanding biopharmaceutical R&D, and advancements in drug manufacturing technologies, the sector presents lucrative opportunities for existing players and new entrants alike. Companies that invest in technology, strategic partnerships, and niche therapeutic areas are well-positioned to capture significant market share, making the U.S. CMO/CDMO landscape a dynamic and high-potential segment of the global pharmaceutical industry.
Read Related Reports:
Surgical Imaging Market
Gastrointestinal Stromal Tumor Market
